ARA-290

Quickstart Highlights

Ara-290 (cibinetide) is an 11–amino acid non-erythropoietic peptide derived from erythropoietin’s helix-B domain. It selectively activates the innate repair receptor (IRR), an EPOR/CD131 heterodimer, to promote anti-inflammatory and tissue-protective effects without stimulating red blood cell production. Clinical trials have demonstrated benefits for diabetic neuropathy and sarcoidosis-related small-fiber neuropathy.

• Reconstitute: Add 1.0 mL BAC water per labelled 10 mg vial; calculations assume a final volume of 1.0 mL and nominal concentration of 10 mg/mL.
• Target dose: 4 mg once daily subcutaneously (after initial 2 mg titration).
• Scale conversion: At 10 mg/mL, 1 U-100 unit = 0.01 mL = 100 mcg. Confirm actual device markings; this arithmetic does not establish measurement accuracy.
• Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); reconstituted: refrigerate and use within 28 days.

Protocol Overview

Concise summary of the once-daily regimen based on clinical trial designs.

• Goal: Support tissue protection, anti-inflammatory signaling, and neuropathic symptom management via IRR activation.
• Schedule: Daily subcutaneous injections for 4 weeks (the 28-day clinical-trial protocol); a second 4-week block only on reassessment, 8 weeks maximum before a break.
• Dose Range: 2–4 mg daily; 4 mg is the established target dose.
• Reconstitution: 1.0 mL BAC per labelled 10 mg vial; nominal 10 mg/mL under the stated final-volume assumption.
• Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated up to 28 days.

Dosing Protocol

Suggested daily approach reflecting clinical study parameters.

• Start: 2 mg daily during week 1 to assess tolerance.
• Target: 4 mg daily from week 2 through week 4.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 4 weeks standard (28 days); 8 weeks maximum, then at least 4 weeks off. No 16-week extension.
• Timing: Any consistent time daily; rotate injection sites.

Storage Instructions

Proper storage preserves peptide integrity and potency.

• Lyophilized: Refrigerate at 2–8 °C (35.6–46.4 °F) for up to 2 years; freeze at −20 °C (−4 °F) for extended storage up to 3 years.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days and do not freeze the liquid solution.
• Allow vials to reach room temperature before opening to minimize condensation; protect from light.
• Discard if discoloration, cloudiness, or particulate matter is observed.

Important Notes

Practical considerations for consistency and safety.

• Use a new sterile insulin syringe for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and injection site to maintain consistency.
• No clinically significant adverse effects were reported at 4 mg/day in 28-day clinical trials.

How This Works

Ara-290 (cibinetide) binds to the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (βc subunit), which is distinct from the classical erythropoietin receptor. This selective binding triggers anti-apoptotic and anti-inflammatory signaling cascades that protect tissues and promote repair without stimulating erythropoiesis. Preclinical research demonstrates that Ara-290 can reprogram a pro-inflammatory, tissue-damaging environment into one favoring healing and regeneration. Additionally, analgesic effects have been observed through immunomodulation and direct inhibition of TRPV1 ion channels activated by capsaicin.

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

• Neuroprotection: Clinical trials in diabetic neuropathy showed improvements in HbA1c, lipid profiles, and neuropathic pain scores with 4 mg daily dosing.
• Nerve regeneration: In sarcoidosis-associated small-fiber neuropathy, treatment led to significant increases in corneal nerve fiber density (objective nerve regrowth) and improved symptoms compared to placebo.
• Tissue protection: Anti-inflammatory and anti-apoptotic effects observed across multiple organ systems in preclinical models.
• No erythropoietic effects: Unlike full EPO, Ara-290 does not stimulate red blood cell production, avoiding related side effects.
• Tolerability: Well tolerated in clinical studies; occasional mild injection-site reactions (redness, transient discomfort) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies that may support therapeutic goals.

• Optimize glycemic control through diet and medication adherence if addressing diabetic neuropathy.
• Incorporate regular physical activity appropriate to individual capacity to support nerve health and circulation.
• Prioritize adequate sleep and stress management to support tissue repair processes.
• Avoid smoking and limit alcohol consumption, both of which can exacerbate neuropathic conditions.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

• Clean the vial stopper and injection site with alcohol swabs; allow to dry completely.
• Select a fatty subcutaneous site: lower abdomen (at least 2 inches from navel), outer thigh, or back of upper arm.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
• Aspiration is not required for subcutaneous injections; inject slowly and steadily.
• Rotate sites systematically with each dose to avoid lipohypertrophy and local tissue changes.
• After injection, withdraw the needle and apply gentle pressure with clean gauze; do not rub the site.

Recommended Source

We recommend Amino Labs for high-purity ARA-290 (10 mg vials).

Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Amino Labs